Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy

As one of the most common microvascular complications of diabetes mellitus,diabetic nephropathy(DN) is a common cause of end-stage renal disease(ESRD).Sodium-glucose cotransporter 2(SGLT-2) inhibitor,a new type of hypoglycemic agent,may effectively lower blood glucose,improve renal hyperfiltration,lower blood pressure,reduce urinary protein,improve renal hypoxia,reduce inflammation and oxidative stress,lower serum uric acid,weight and plasma lipids,etc.This review summarized its protective mechanism on DN.